Eric Luster
Psychiatric/Mental Health · Little Rock, ARNPI 1003564154
Payments from drug & device makers
Across 124 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$836
- Otsuka America Pharmaceutical, Inc.$358
- AbbVie$307
- Johnson & Johnson$205
- E.r. Squibb & Sons, L.L.C.$168
- Alkermes, Inc.$120
- plus $466 from 9 others
What the payments were for
- Food & beverage$2,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,459 in reported general payments places this provider in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 54 | $80,089 |
| RexultiBrexpiprazole | 36 | $74,171 |
| AustedoDeutetrabenazine | 13 | $62,434 |
| Invega SustennaPaliperidone Palmitate | 16 | $59,072 |
| Quetiapine Fumarate | 121 | $2,852 |
| Fluoxetine Hcl | 76 | $2,804 |
| Atomoxetine Hcl | 30 | $2,308 |
| Buspirone Hcl | 204 | $2,186 |
| Hydroxyzine Pamoate | 92 | $2,085 |
| Aripiprazole | 68 | $1,847 |
| Ziprasidone Hcl | 26 | $1,628 |
| Duloxetine Hcl | 73 | $1,262 |
| Haloperidol Decanoate | 14 | $1,198 |
| Hydroxyzine Hcl | 39 | $909 |
| Bupropion XlBupropion Hcl | 53 | $773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $307 | $80,08954 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $358 | $74,17136 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $13 | $62,43413 claims |
| Johnson & JohnsonInvega Sustenna | $205 | $59,07216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Little Rock
- Cara MeckfesselLittle Rock$8K
- Stacey HughesLittle Rock$7K
- Michelle HeadLittle Rock$6K
- Sara JonesLittle Rock$6K
- Alicia BarosLittle Rock$6K
- Adrianne FunmakerLittle Rock$5K
- Chloe WardLittle Rock$4K
- Ashley TaylorLittle Rock$4K
- Kizzie HoustonLittle Rock$3K
- Jennifer RawlsLittle Rock$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.